ADXS Advaxis Inc.

2.29
0  0%
Previous Close 2.29
Open
Price To Book 0.43
Market Cap 18,367,666
Shares 8,020,815
Volume 161
Short Ratio
Av. Daily Volume 239,690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1 monotherapy, overall survival was 8.5 months, combo with Keytruda 23 months.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 partial clinical hold lifted - May 15, 2019.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
ADXS-HER2
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-NEO
Non-small cell lung cancer (NSCLC)
Phase 1/2 preliminary data due 2H 2019.
ADXS-HOT 503
Non-small cell lung cancer (NSCLC)

Latest News

  1. Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT
  2. Advaxis, Inc. to Host Earnings Call
  3. Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
  4. Advaxis to Host Business Update Conference Call on June 11, 2019
  5. What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
  6. Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
  7. FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
  8. Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
  9. Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
  10. Advaxis to Participate in Five Upcoming Industry Conferences
  11. Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
  12. QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
  13. Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
  14. Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
  15. Why Range Resources, Advaxis, and StoneCo Slumped Today
  16. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  17. Advaxis' stock plummets after public offering prices at deep discount
  18. Advaxis Announces Pricing of Its Public Offering of Common Stock
  19. Advaxis, Inc. Announces Proposed Public Offering of Common Stock
  20. Advaxis Up on Positive Early-Stage Immunotherapy Study Data